What is SNORD115-8? (G100033445)

Target Name: SNORD115-8

NCBI ID: G100033445

SNORD115-8

Other Name(s): HBII-52-8 | small nucleolar RNA, C/D box 115-8 | Small nucleolar RNA, C/D box 115-8

What is SNORD115-8?

SNORD115-8 is a small nucleolar RNA molecule that plays a crucial role in various cellular processes. This specific RNA belongs to the SNORD115 family, which is found in humans and other mammals. SNORD115-8 is transcribed from a region of chromosome 15q11-q13, which is commonly associated with neurodevelopmental disorders and imprinting disorders, such as Prader-Willi syndrome and Angelman syndrome.

Link to Disease

SNORD115-8 has been extensively studied for its potential involvement in disease development, particularly in neurodevelopmental disorders. Prader-Willi syndrome (PWS) and Angelman syndrome (AS) are two examples of imprinting disorders that have been associated with abnormalities in the SNORD115-8 gene.

PWS is a complex genetic disorder characterized by various symptoms, including hyperphagia (excessive eating), intellectual disabilities, and behavioral problems. The loss of SNORD115-8 expression in the PWS region of chromosome 15q11-q13 has been linked to the pathogenesis of PWS. SNORD115-8 appears to play a critical role in the regulation of other genes in this region, and its deficiency disrupts the normal development and functioning of certain brain regions, leading to the observed symptoms.

Similarly, AS is another imprinting disorder caused by abnormalities in the same chromosomal region. SNORD115-8 is also absent or diminished in individuals with AS, suggesting its important role in the development and function of the brain. AS is characterized by severe intellectual disabilities, developmental delays, and motor coordination impairments. The absence of SNORD115-8 may contribute to the dysfunction of specific brain circuits, leading to the manifestation of AS symptoms.

SNORD115-8 as a Potential Drug Target

The involvement of SNORD115-8 in neurodevelopmental disorders presents it as a potential drug target for therapeutic intervention. Since the loss of SNORD115-8 expression is a key component of PWS and AS pathogenesis, finding ways to restore or enhance its expression could help alleviate the symptoms associated with these disorders.

One approach to target SNORD115-8 could involve gene therapy techniques. Researchers are exploring the use of viral vectors to deliver functional copies of the SNORD115-8 gene into the affected brain regions. By reintroducing SNORD115-8, it might be possible to restore the normal gene expression pattern, thereby reversing the molecular and cellular dysfunctions associated with PWS and AS.

Another potential avenue for drug targeting is through the modulation of factors involved in SNORD115-8 gene regulation. Understanding the molecular mechanisms that control the expression of SNORD115-8 could lead to the identification of druggable targets that can enhance its expression. Small molecules, such as small interfering RNAs or antisense oligonucleotides, could potentially be employed to modulate specific regulatory proteins or elements, thereby increasing SNORD115-8 expression.

SNORD115-8 as a Biomarker

Besides its potential as a drug target, SNORD115-8 could also serve as a biomarker for the diagnosis and monitoring of neurodevelopmental disorders. Currently, the diagnosis of PWS and AS relies on clinical evaluations and genetic testing. However, the emergence of SNORD115-8 as a biomarker may offer a more precise and reliable diagnostic tool.

By analyzing the expression levels of SNORD115-8 in patient samples, medical professionals could identify individuals with PWS or AS more accurately. Additionally, monitoring changes in SNORD115-8 expression over time could provide insights into disease progression or response to treatments.

Conclusion

SNORD115-8 represents an intriguing molecule with significant implications in neurodevelopmental disorders. Its association with Prader-Willi syndrome and Angelman syndrome has provided valuable insights into the molecular mechanisms underlying these disorders. As a potential drug target, strategies to restore or enhance SNORD115-8 expression could hold promise in alleviating the symptoms of PWS and AS. Furthermore, SNORD115-8 has the potential to serve as a biomarker for the diagnosis and monitoring of these neurodevelopmental disorders. Continued research efforts in this field could lead to improved therapies and diagnostic tools, ultimately improving the lives of individuals affected by these conditions.

Protein Name: Small Nucleolar RNA, C/D Box 115-8

The "SNORD115-8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD115-8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets